Opinion|Videos|March 28, 2025
Tailoring Immunotherapy Strategies for the Advanced NSCLC
Panelists discuss how treatment decisions for advanced non–small cell lung cancer (NSCLC) without actionable mutations depend on factors like PD-L1 status, histology (eg, squamous [SQ]), and biomarkers like STK11/KEAP1. Chemotherapy may be added based on individual patient factors, with promising advancements expected in 2025.
Advertisement
Video content above is prompted by the following:
- How do you select between mono immunotherapy (IO) and dual IO therapy in patients with advanced NSCLC and no actionable mutations?
- In which patients do you consider the addition of chemotherapy?
- How does PD-L1 status influence your decision?
- What is your preferred management strategy for patients with SQ histology? STK11 or KEAP1? What data influence your treatment approach?
- What advancements in lung cancer from 2024 will have the most significant impact on your clinical practice in 2025?
- What do you see as the greatest treatment gaps and unmet needs in the management of advanced NSCLC, and what are the most promising opportunities for future advancements?
Advertisement
Related to this article
The WVU Heart and Vascular Institute and WVU Cancer Institute performed West Virginia’s first single-port robotic-assisted thoracoscopic lobectomy.
The MHLW approval covers all lines of therapy, including first-line use, in unresectable advanced or recurrent HER2-mutant NSCLC.
UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.
Obesity can weaken the immune system and lead to disease progression, but Roswell Park experts revealed that exercise may reverse that effect.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The oral OMNI-EGFR inhibitor earned fast track status for advanced EGFR C797S–positive non–small cell lung cancer that progressed on a third-generation EGFR TKI.
T-DXd improved PFS in the phase 3 DESTINY-Lung04 trial for first-line HER2-mutant NSCLC.
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
The phase 3 eVOLVE-Lung02 trial is being discontinued after its IDMC found volrustomig plus chemotherapy unlikely to meet its dual primary end points.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Rusfertide for Polycythemia Vera
2
The OncFive: Top Oncology Articles for the Week of 8/23
3
First-Line Ivonescimab Plus Chemotherapy Meets OS End Point in Advanced Biliary Tract Cancer
4
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
5